ZIMVIE Stock Price, News & Analysis
Company Description
ZimVie Inc. (historically traded on Nasdaq under the symbol ZIMV) is described in its public communications as a global life sciences leader in the dental and dental implant market. The company develops, manufactures, and delivers a portfolio of products and solutions designed to support dental tooth replacement and restoration procedures. According to multiple company news releases, ZimVie focuses on comprehensive tooth replacement solutions, including trusted dental implants, biomaterials, and digital workflow solutions that aim to improve smiles, function, and confidence in daily life.
ZimVie reports that it operates from headquarters in Palm Beach Gardens, Florida, with additional facilities around the globe. Its communications emphasize a commitment to advancing clinical science and technology that are foundational to restoring daily life for patients undergoing dental implant and restorative procedures. The company positions itself as a worldwide leader in its space, focusing on dental implants and related digital and biomaterial offerings.
Business focus and product themes
Across its press releases, ZimVie describes a business centered on dental implant systems and connected solutions that support clinicians through the full treatment workflow. The company highlights tooth replacement and restoration procedures as its primary clinical area. Within that focus, ZimVie references:
- Dental implants intended for tooth replacement procedures.
- Biomaterials used in conjunction with implant and restorative dentistry.
- Digital workflow solutions that support planning, placement, and restoration.
In one announcement, ZimVie describes an exclusive distribution agreement that expands its premium dental implant offering in China, indicating that its implant portfolio is designed for precision, esthetics, and durability. In another release, the company details the launch of its RealGUIDE software suite and Implant Concierge service in Japan, describing these as part of a digital dental implant ecosystem covering implant planning, surgical guides, restorative design, and guided surgery support.
Digital dentistry and workflow solutions
ZimVie states that it offers digital workflow solutions that integrate planning, design, and restorative steps. The RealGUIDE software suite is described as a cloud-based solution with software modules that can be combined for diagnosis, intended implant positioning, surgical guide design, and restorative design and manufacturing. The company notes that RealGUIDE is integrated with its fully owned dental laboratory Dental Technology Institute (DTI) in Japan and its CAD/CAM milling workflow to provide a digital experience from case planning to final restoration.
The company also describes Implant Concierge as a virtual outsourcing service that simplifies and streamlines implant treatment planning and guided surgery. According to ZimVie, this platform consolidates essential services to reduce complexity and accelerate case turnaround, and is designed to be scalable for high-volume practices while integrating with dental laboratories.
Geographic footprint and partnerships
In its public statements, ZimVie characterizes itself as a global company with facilities around the world. Specific communications highlight activity in several regions. The company identifies Japan as its largest market in the Asia-Pacific region for dental implants and notes the launch of RealGUIDE and Implant Concierge there. In China, ZimVie has announced an exclusive distribution agreement with Osstem Implant Co., Ltd. under which Osstem Implant has exclusive commercial responsibility for ZimVie implant systems in the Chinese market. ZimVie describes this arrangement as a way to expand its presence in a large and growing implant market and to enhance customer access to its implant portfolio.
Corporate transaction and trading status
According to a Globe Newswire release dated October 20, 2025, and related SEC filings, ZimVie entered into an Agreement and Plan of Merger with an affiliate of ARCHIMED, an investment firm focused on healthcare industries. The company reported that ARCHIMED agreed to acquire all outstanding shares of ZimVie common stock for cash consideration per share. Following stockholder approval described in an October 10, 2025 special meeting 8-K, ZimVie announced the completion of the acquisition by ARCHIMED on October 20, 2025.
In that completion announcement, ZimVie stated that, as a result of the transaction, its common stock no longer trades on the Nasdaq stock exchange and that the company has become a privately held entity. An earlier 8-K filing and related disclosures indicated that, upon completion of the merger, the common stock would be delisted from the Nasdaq Global Select Market and deregistered under the Securities Exchange Act of 1934, with the company surviving as a wholly owned subsidiary of the acquiring parent.
Regulatory reporting and financial communication
While it was a public company, ZimVie filed periodic reports and current reports with the U.S. Securities and Exchange Commission and issued earnings releases. For example, the company reported first quarter and second quarter 2025 financial results in press releases that discussed net sales from continuing operations, net loss from continuing operations, adjusted EBITDA, and adjusted diluted earnings per share, along with reconciliations of non-GAAP measures to GAAP metrics. These releases also referenced the use of non-GAAP financial measures, constant currency sales change information, and management’s rationale for using such measures.
In connection with the merger process, ZimVie filed multiple Form 8-K reports describing entry into the merger agreement, the go-shop period, stockholder approvals, and supplemental proxy disclosures. One 8-K detailed litigation matters related to the proxy statement and summarized additional disclosures the company chose to make in response to stockholder complaints, while reiterating that the company believed the allegations were without merit.
Positioning within dental and life sciences
Throughout its communications, ZimVie emphasizes its role in the dental and dental implant market as a company that supports clinicians with implants, biomaterials, and digital workflows. The company’s descriptions focus on improving clinical outcomes related to tooth replacement and restoration, and on supporting dental professionals with tools that aim to enhance efficiency, accuracy, and esthetic results in implant dentistry. Its agreements, such as the distribution partnership in China and the launch of digital tools in Japan, are presented as ways to broaden access to its implant systems and digital solutions in key markets.